| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8f55539cd116885650d6eaeb65b0207 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24032 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-02 |
| filingDate |
2006-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fecbe760d8c242a1fe4efbb8da1a3fc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d53a2a6966edcc88ec7df91deec4d450
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954615d2afc60f8e52b1555de0a7cf51 |
| publicationDate |
2009-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1863906-A4 |
| titleOfInvention |
USE OF MYXOMA VIRUS AND RAPAMYCIN COMBINATION FOR THERAPEUTIC TREATMENT |
| abstract |
The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R. |
| priorityDate |
2005-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |